Opko Health (OPK) risk factors, FY2024 10-K

RISKS RELATED TO OUR BUSINESS

1. 01We have had a history of operating losses and may not be able to achieve profitability in the near future
2. 02We may require additional funding, which may not be available to us on acceptable terms, or at all
3. 03Our research and development activities may not result in commercially viable products
4. 04The results of pre-clinical trials and previous clinical trials for our products may not be predictive of future results, and our current and planned clinical trials may not satisfy the requirements of the FDA or other non-U.S. regulatory authorities
5. 05We rely on licensing agreements with VFMCRP, Nicoya, and international partners for the international development and marketing of Rayaldee. Failure to maintain these license agreements could prevent us from successfully developing and commercializing Rayaldee worldwide
6. 06Our exclusive worldwide agreement with Pfizer is important to our business. If we do not successfully develop Somatrogon (hGH- CTP) and/or Pfizer does not successfully commercialize Somatrogon (hGH-CTP ), our business could be adversely affected
7. 07Our business is substantially dependent on our ability to achieve regulatory approval for the marketing of Somatrogon (hGH-CTP) in pediatric patients and the commercial success of this product
8. 08Our business depends on our ability to generate profits and cash flow from our laboratory operations
9. 09From time to time, manufacturers discontinue or recall reagents, test kits or instruments used by us to perform laboratory testing. Such discontinuations or recalls could adversely affect our costs, testing volume and revenue
10. 10If our competitors develop and market products or services that are more effective, safer or less expensive than our current and future products or services, our revenues, profitability and commercial opportunities will be negatively impacted
11. 11Our product development activities could be delayed or stopped
12. 12insufficient liquidity to fund our preclinical and clinical studies
13. 13insufficient liquidity to fund ongoing studies
14. 14Our inability to meet regulatory quality standards applicable to our manufacturing and quality processes and to address quality control issues in a timely manner could delay the production and sale of our products or result in recalls of products
15. 15We manufacture pharmaceutical products in Ireland, Mexico, Spain, and Israel. Any quality control issues at our facilities may weaken our competitive position and have a material adverse effect on our business results of operations and financial condition
16. 16Failure to establish, and perform to, appropriate quality standards to assure that the highest level of quality is observed in the performance of our testing services could adversely affect the results of our operations and adversely impact our reputation
17. 17Even after we receive regulatory approval or clearance to market our product candidates, the market may not be receptive to our products
18. 18changes in the standard of care for the targeted indications for any of our products or product candidates, which could reduce the marketing impact of any claims that we could make following applicable regulatory authority approval
19. 19If our products are not covered and eligible for reimbursement from government and third party payors, we may not be able to generate significant revenue or achieve or sustain profitability
20. 20Our success is dependent to a significant degree upon the involvement, efforts and reputation of our Chairman and Chief Executive Officer, Phillip Frost, M.D
21. 21If we fail to attract and retain key management and scientific personnel, we may be unable to successfully operate our business and develop or commercialize our products and product candidates
22. 22Business combinations may disrupt our business, distract our management, may not proceed as planned, and may also increase the risk of potential third party claims and litigation
23. 23If the FDA or other applicable regulatory authorities approve generic products that compete with any of our products or product candidates, the sale of our products or product candidates may be adversely affected
24. 24We rely on third parties to manufacture and supply our pharmaceutical and diagnostic products and product candidates
25. 25Independent clinical investigators and contract research organizations that we engage to conduct our clinical trials may not be diligent, careful or timely
26. 26Failure to timely or accurately bill and collect for our services could have a material adverse effect on our revenues and our business
27. 27We have in the ordinary course of business been the subject of recoupments by payors and have from time to time identified and reimbursed payors for overpayments
28. 28The information technology systems that we rely on may be subject to unauthorized tampering, cyberattack or other data security incidents that could impact our billing processes or disrupt our operations
29. 29We also face efforts by non-governmental third-party payors, including healthcare plans, to reduce utilization and reimbursement for clinical testing services
30. 30The increased consolidation among healthcare plans also has increased the potential adverse impact of ceasing to be a contracted provider with any such insurer
31. 31If we are unable to obtain and enforce patent protection for our products, our business could be materially harmed
32. 32If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected
33. 33We will rely heavily on licenses from third parties. Failure to comply with the provisions of these licenses could result in the loss of our rights under the license agreements
34. 34We license patent rights to certain of our technology from third-party owners. If such owners do not properly maintain or enforce the patents underlying such licenses, our competitive position and business prospects will be harmed
35. 35Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties
36. 36If we become involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial costs and expenses, substantial liability for damages or be required to stop our product development and commercialization efforts
37. 37We have faced, and may in the future face, intellectual property infringement claims that could be time-consuming and costly to defend, and could result in our loss of significant rights and the assessment of treble damages
38. 38We may become subject to product liability claims for our diagnostic tests, clinical trials, pharmaceutical products and medical device products
39. 39Adverse results in material litigation matters or governmental inquiries could have a material adverse effect upon our business and financial condition
40. 40The ongoing Russia-Ukraine conflict and the recent Israel-Hamas conflict may adversely impact our business operations and financial performance

RISKS RELATED TO REGULATORY COMPLIANCE

1. 41Our ability to successfully operate our laboratories and develop and commercialize certain of our diagnostic tests and LDTs will depend on our ability to maintain required regulatory licensures and comply with all the CLIA requirements
2. 42The regulatory approval process is expensive, time consuming and uncertain and may prevent us or our collaboration partners from obtaining approvals for the commercialization of some or all of our product candidates
3. 43refusal to approve or clear pending NDAs or supplements to approved NDAs, applications or pre-market notifications
4. 44The terms of approvals and ongoing regulation of our products may limit how we manufacture and market our products and product candidates, which could materially impair our ability to generate anticipated revenues
5. 45If we fail to comply with complex and rapidly evolving laws and regulations, we could suffer penalties, be required to pay substantial damages or make significant changes to our operations
6. 46changes to other federal, state and local laws, regulations and rules, including tax laws
7. 47Failure to maintain the security of patient-related information or compliance with security requirements could damage our reputation with customers, cause us to incur substantial additional costs and become subject to litigation
8. 48Our failure or the failure of third-party payors or physicians to comply with ICD-10-CM Code Set, and our failure to comply with other emerging electronic transaction standards could adversely impact our business
9. 49Failure to comply with complex federal and state laws and regulations related to submission of claims for clinical laboratory services could result in significant monetary damages and penalties and exclusion from the Medicare and Medicaid programs
10. 50Changes in regulation and policies, including increasing downward pressure on health care reimbursement, may adversely affect reimbursement for diagnostic services and could have a material adverse impact on our business
11. 51Medicare legislation and future legislative or regulatory reform of the health care system may affect our ability to sell our products profitably

RISKS RELATED TO INTERNATIONAL OPERATIONS

1. 52Failure to obtain regulatory approval outside the U.S. will prevent us from marketing our products and product candidates abroad
2. 53Non-U.S. governments often impose strict price controls, which may adversely affect our future profitability
3. 54Potential political, economic and military instability in the State of Israel, where we have office, laboratory and manufacturing operations, may adversely affect our results of operations
4. 55Due to the international scope of our business activities, our results of operations may be significantly affected by currency fluctuations
5. 56We may be exposed to liabilities under the Foreign Corrupt Practices Act, and any determination that we violated the Foreign Corrupt Practices Act could have a material adverse effect on our business
6. 57We are subject to risks associated with doing business globally

RISKS RELATED TO ACQUISITIONS AND INVESTMENTS

1. 58We have a large amount of goodwill and other intangible assets on our balance sheet that are subject to periodic impairment evaluations

RISKS RELATED TO OWNERSHIP OF OUR COMMON STOCK

1. 59The trading price of our Common Stock may fluctuate significantly
2. 60general market conditions and other factors, including factors unrelated to our operating performance
3. 61Directors, executive officers, principal stockholders and affiliated entities own a substantial amount of our capital stock, and they may make decisions that you do not consider to be in the best interests of our stockholders
4. 62A significant short position in our Common Stock could have a substantial impact on the trading price of our stock
5. 63The volatility of our stock may cause the value of a stockholder’s investment to decline rapidly. Additionally, if our stock price declines, it may be more difficult for us to raise capital and may have other adverse effects on our business
6. 64Compliance with changing regulations concerning corporate governance and public disclosure may result in additional expenses